Sichenzia Ross Ference Carmel LLP represents Calidi Biotherapeutics, Inc. in $5.1 Million At The Market Offering

Press Release – New York, NY – October 11, 2024 – Sichenzia Ross Ference Carmel LLP announced that it previously represented Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (the “Company”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, in an at-the-market offering worth up to $5.1 million. The agreement with Ladenburg Thalmann & Co. Inc., dated October 11, 2024, allows the Company to issue and sell shares of common stock from time to time at prevailing market prices or through negotiated transactions.

The SRFC team was led by partner Jay Yamamoto and associate Rohini Sud.